Redefining First-Line EGFR+ NSCLC with Subcutaneous Amivantamab & LazertinibByNicolas Girard, MD, PhDApril 2nd 2026
FDA Grants Breakthrough Therapy Designation to Plixorafenib for BRAF V600E GliomaBySabrina SeraniApril 2nd 2026
Recognizing Renal Medullary Carcinoma: Red Flags for Community OncologistsByPavlos Msaouel, MD, PhDApril 1st 2026